Autologous keratinocyte cultures and combinations of scaffolds, different cell types, solutions of macromolecules, or growth factors have contributed to the resurfacing of burns and large wounds. There are, however, significant limitations with these therapies. No tissue-engineered substitute can fully replace the split-thickness skin graft for permanent coverage of full-thickness skin loss in one step, and none contain a functional vascular plexus. Current research characterizes skin as more than a barrier with sensory function, but as an intricate biological factory participating in cell signaling, metabolism, and protein synthesis, and as a vital component of the nervous, immune and endocrine systems. This paper provides a comprehensive review of the structure and function of skin, highlighting the importance of regenerating an organ that will function physiologically.
The clinical use of honey has gained significant importance in regenerative medicine owing to its constructive properties that abets the rapid healing of broad-spectrum of injuries. The salient characteristics of honey are attributable to its active ingredients which include sugars, enzymes and vitamins. Moreover, the evidence based results exert that honey acts in synergy with its immunologic modulators and physiologic mediators in multitude of signalling pathways and molecular targets offering beneficial vigor effects in wound healing. The aim of this present study is to systematically review the literature in PubMed database in order to identify the available pre-clinical results in support to rational use of honey in wound management. The results revealed that the active biomolecules of honey assisted in improved autolytic debridement and tissue granulation. This review highlights the physiological basis for the use of honey in wound healing, its current pre-clinical uses and its future recommendations.
The major problem in the management of burn wounds are infections. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the major cause of infection in burn wounds. Antibiotic resistant bacteria around the world has become a major therapeutic challenge. Bacteriophages and their lysine are suggested as an antimicrobial alternative agent. Phage display technique is suggested for production of recombinant lysine by Nano carrier technology. The approach of this study was to evaluate the potential of recombinant Nano phage efficacy in MRSA burn wound infection in vivo. The 3rd degree burn wounds were induced in 54 rats and infected with MRSA ATCC 33591 via the topical route in four groups. Burn wound size was measured in 0, 14, 21, 28 days. The efficacy of Nano phage gel was assessed on the basis of percentage collagen deposition, granulation tissue, neovascularization, fibroblastic maturity, re-epithelization, and scar formation in rats following treatment in 14, 21, 28 days. The results showed that the percentage of wound size were 3 cm on base line day and the average macroscopic wound healing rates were increased in the prevention groups receiving the recombinant Nano phage gel and natural phage gel, in the treatment groups with secondary infection receiving the recombinant Nano phage gel and the natural phage gel, and in the two control groups respectively. The average microscopic wound healing rates were increased in the prevention groups receiving the recombinant Nano phage gel and natural phage gel, in the treatment groups with secondary infection receiving the recombinant Nano phage gel and the natural phage gel, and in the two control groups respectively. In conclusion the recombinant Nano phage gel is efficacy to treat and prevent MRSA burn wound infection.
Abstract Background The use of Theresienol® (T.O.) a traditional Austrian natural product has been traced back to1350. Medical wound care has always been a major concern and problem for people, especially in the Middle Ages. Еven the smallest injuries or open wounds to become fatal due to poor hygienic conditions. Access to natural fats and vegetable ingredients made it possible to create a unique ointment named Theresienol® which successfully treated multiple skin injuries including wounds, burns and scars. Methods 1,354 patients suffering of therapy-refractory skin injuries treated with T.O. within 38 centers between 2004–2020 in a cohort study. These were used for this review. Patients were divided by clinical criteria based on application duration and daily rate of reapplication strictly individualized depending on the degree of damage and efficiency results depending on the duration of the problem and the presence of chronic concomitant diseases. With a simplified application process a fine film of 2 drops/1 cm of the product (Depending on the vehicle of choice) over the wound or the affected areas, with a waiting time until partial absorption takes place followed by the dressing. It can be applied directly over the wound or over sterile bandages. The Primary endpoints were pain reduction, patient satisfaction both physically and aesthetically. Additionally we performed dermatological testing for irritation and allergy potential and rule out further side effects. Results After further evaluation of the 1,354 cases, statistically it showed an averaged of 89 % improvement rate in inflammation, an 88 % reduction rate in pruritus, 87 % of improved epithelisation, 93 % in patient benefit, and 91 % show improvement in wound closure. The Visual Analogue Scale of pain started at 8.29 a marked reduction was noted in the first 24 h with an average of 2.41. followed by a stable slow reduction of 1.73 on the 7th day. Conclusion Treatment of Therapy-Refractory skin injuries including burns, scars, acute in addition to chronic wounds with T.O., which is nearly 700 years old has shown for the first time exceptional results in an outpatient setting and was successful in alleviating inflammation, pain, itching and discomfort associated with wound care, thus providing an optimal opportunity for the wound to heal sufficiently and quickly without reported side effects.
•Overview of matrix therapy agent CACIPLIQ20® used as last resort for chronic wounds.•119 healed wounds were evaluated to assess healing time with CACIPLIQ20® treatment.•Wound types included diabetic foot ulcers, burns, post-amputation/surgical wounds.•Complete healing was achieved in 2 months regardless of wound size, age or etiology.•CACIPLIQ®20 treatment was cost-effective costing 74 euros/64 GBP per wound.•Marked pain relief as a consequence of healing was also reported.
